Topical Insulin – Utility and Results in Neurotrophic Keratopathy Types 2 and 3

Learn more about:
Related Clinical Trial
QST for Corneal Nerve Function An Investigator-Initiated Study to Assess the Association of Diabetic Retinopathy Severity Scale (DRSS) With Level of Decreased Corneal Sensitivity Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2 DEFENDO Long Term Follow-up Study in Stage 1 NK Patients Topical Insulin Drops for the Treatment of Neurotrophic Keratopathy. Phase 2 Clinical Trial to Evaluate OC-01 Nasal Spray in Subjects With Neurotrophic Keratopathy Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Neurotrophic Keratitis Subjects Topical Insulin – Utility and Results in Neurotrophic Keratopathy Types 2 and 3 Corneal Nerves After Treatment With Cenegermin Autologous Platelet-rich Plasma (APRP) in the Treatment of Neurotrophic Keratopathy OCT Evaluation of Neurotrophic Ulcer Following Treatment With Oxervate Nerve Growth Factor for the Treatment of Cornea Disease Study to Evaluate OXERVATE™ in Patients With Stage 1 Neurotrophic Keratitis Efficacy and Safety of Plasma Rich in Growth Factors (PRGF-Endoret) Eye-drops in the Treatment of Neurotrophic Keratitis REC 0/0559 Eye Drops for Treatment of Moderate and Severe Neurotrophic Keratitis in Adult Patients Evaluation of Efficacy of 20 µg/ml rhNGF New Formulation (With Anti-oxidant) in Patients With Stage 2 and 3 NK Evaluation of Safety and Efficacy of rhNGF in Patients With Stage 2 and 3 Neurotrophic Keratitis. Miniinvasive Corneal Neurotization. A Pilot Study. Study to Evaluate Safety, Tolerability & PK of rhNGF in Healthy Volunteers An 8-week Follow-up to Evaluate the Renewal of Corneal Nerves Structure and Function in Patients With Neurotrophic Keratopathy Treated With Recombinant Human Nerve Growth Factor (rhNGF) Eyedrops A Clinical Trial to Asses Efficacy and Safety of Cord Blood Eye Drops in Neurotrophic Keratopathy Assessment of the Safety and Efficacy Study of RGN-259 Ophthalmic Solutions for Neurotrophic Keratopathy : SEER-1

Recruitment Information


Administrative Informations